Vemurafenib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Vemurafenib
Vemurafenib: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Vemurafenib, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| melanoma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 11076Y | Zelboraf | Tablet 240 mg | Valid |
Cytotoxicity
Vemurafenib is an antineoplastic, targeted-therapy BRAF inhibitor rather than a conventional cytotoxic agent.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BRAF kinase inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI. The compiled data and literature point to dermatological and ocular monitoring (rash, uveitis) and ECG/electrolyte monitoring (QT-related). |
| Handling Protection | Please refer to the PI and local institutional policy |
Safety Considerations
Contraindication signals from the knowledge graph (model-derived drug-disease links, not label text):
- Cardiac and electrolyte: long QT syndrome (including familial), torsades de pointes, potassium deficiency, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease
- Hepatic: hyperbilirubinaemia, hereditary hyperbilirubinaemia, Gilbert syndrome
- Ocular: uveitis, iris disease, ciliary body disease, panuveitis, iritis
The ocular signal is consistent with published reports of vemurafenib-associated uveitis (PMID 32546073).
Drug interactions: 100 interactions were identified. Those listed as Major:
- Clarithromycin
- Dolasetron
- Palonosetron
Moderate-level examples include famotidine, pioglitazone, dexamethasone, aprepitant, loperamide, sitagliptin, saxagliptin, linagliptin, naltrexone and several bowel-preparation agents. Many of the QT-relevant combinations are particularly relevant given the knowledge-graph QT signals.
Disease-specific concern: One case report describes vemurafenib-induced progression of breast cancer (PMID 26264150).
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as label-based data were not available for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.